Abstract: The present disclosure relates to the field of genetic engineering or enzyme engineering, and in particular to an application of MmPI in preparation of trypsin inhibitors. The amino acid sequence of the MmPI is shown in SEQ ID NO.1. The present disclosure clarifies for the first time that MmPI in mulberry leaves has trypsin inhibitory activity and reveals its physical and chemical properties. The MmPI has good application prospects in preparing trypsin inhibitors. On the basis of knowing the physical and chemical properties of the MmPI, its activity may be accordingly eliminated, thereby it promotes the development and utilization of mulberry leaf resources in animal feed, provides new perspectives and ideas for the development and utilization of mulberry leaves in animal feed and health food, and enhances the economic benefits of mulberry resources.

Abstract: The present disclosure relates to the field of genetic engineering or enzyme engineering, and in particular to an application of MmBBK2 in preparation of trypsin and chymotrypsin inhibitors. The MmBBK2 has the amino acid sequence shown in SEQ ID NO.1 or SEQ ID NO.2. The present disclosure clarifies for the first time that MmBBK2 in mulberry leaves has both trypsin and chymotrypsin inhibitory activity, and reveals its physical and chemical properties. The MmBBK2 has good application prospects in preparing trypsin and chymotrypsin inhibitors. On the basis of knowing its physical and chemical properties, its activity may be accordingly eliminated, promoting the development and utilization of mulberry leaf resources in animal feed, providing new perspectives and ideas for the development and utilization of mulberry leaves in animal feed and health food, and improving economic benefits of mulberry resources.

Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.

Abstract: Methods and systems are provided for determining the category of a software application utilizing machine learning (ML) and knowledge graph techniques, and for controlling access to the application by a user based on the category and configured time restrictions for the user. The system includes a feature set extractor and a category predictor with a trained ML model. The trained ML model generates the category of the application based on a feature(s) of the application. The generated category is indicated in a data structure. An access request handler receives a request related to access to the application from a user device. A category determiner determines the category of the application from the data structure. A time usage manager determines an available time usage for the category and the specified user. The access arbiter responds to the request from the user device with the available time usage.

Abstract: Provided herein are N-acetylgalactosamine (GalNAc)-derived compounds, modified oligonucleotides, and methods of modulating protein function and treating diseases, disorders, and symptoms in a subject.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of angiotensinogen (AGT). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT protein in a cell or animal.

Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.

Abstract: A pixel system for an imaging device can include one or more pixels comprising a pulse trigger assembly configured to detect a pulse at one or more threshold voltages, a timer system forming part of and/or connected to the one or more pixels, the timer system comprising one or more trigger switches. The pulse trigger assembly can be configured to activate the one or more trigger switches in response to detecting the pulse at the one or more threshold values. The pixel system can include a time-of-flight (TOF) module operatively connected to the one or more pixels and/or the timer system to determine a TOF based on an output from the timer system while simultaneously performing either or both passive imaging and asynchronous laser pulse detection.

Abstract: RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.

Abstract: A positive electrode plate includes a positive electrode current collector and two positive electrode active material layers on both surfaces of the positive electrode current collector. The positive electrode active material layer includes a positive electrode active material and graphene. And 7.74?Dv501/2+0.05 THK?10.2, Dv50 is a particle size of the positive electrode active material and THK is a thickness of the positive electrode plate. And 0.078?w*CW+0.01n?1.9, n is a quantity of layers of the graphene, w is a mass percentage of the graphene in the positive electrode active layer, and CW is a one-side coating weight of the positive electrode active material layer.

Abstract: A voice call method is provided. The method includes: obtaining a voice call state of a terminal system at a historical moment, the terminal system being provided with at least two audio acquisition devices; obtaining first voice signals acquired by the at least two audio acquisition devices at a current moment, and determining signal energy of the first voice signals; and determining a target audio acquisition device at the current moment from the at least two audio acquisition devices based on the voice call state at the historical moment and the signal energy of the first voice signals.

Abstract: An image sensor having a set of pixels making up the image sensor to capture an image. Two or more pixels in the set of pixels each have an architecture that includes multiple photodiodes configurable to form an individual pixel. A control system can cooperate with the multiple photodiodes to form the individual pixel. Each of the multiple photodiodes can have a transfer gate electrically coupled to that photodiode. A common region can hold or transfer charge at least during or after an integration time. A read gate electrically coupled to the common region and a sense node, can supply charge from the common region through the read gate to the sense node.

Abstract: Systems, methods, and software are disclosed herein that provide a computer-based user experience that allows a user to consume information about physical and digital activities undertaken by one or more users. In an implementation, a software application on a computing device communicates with an online service to obtain activity information indicative of such activities, as well as activity topics produced by the service. The application groups the activities into activity groups based at least on the topics produced for the activities, and displays the activity groups in a user interface to the application.

Abstract: A multi-channel echo cancellation method includes obtaining far-end audio signals outputted by channels, obtaining a filter coefficient matrix corresponding to a kth frame of microphone signal outputted by a target microphone and including frequency domain filter coefficients of filter sub-blocks corresponding to the channels, performing frame-partitioning and block-partitioning processing on the far-end audio signals to determine a far-end frequency domain signal matrix corresponding to the kth frame of microphone signal and including far-end frequency domain signals of the filter sub-blocks, performing filtering processing according to the filter coefficient matrix and the far-end frequency domain signal matrix to obtain an echo signal in the kth frame of microphone signal, and performing echo cancellation according to a frequency domain signal of the kth frame of microphone signal and the echo signal in the kth frame of microphone signal to obtain a near-end audio signal outputted by the target microphone.

Abstract: A method of making a semiconductor structure, the method including providing a silicon on insulator (SOI) substrate having a first epitaxial layer and a bulk silicon substrate separated by a buried oxide layer. The method further includes performing a local oxidation of silicon (LOCOS) process in a region of the SOI substrate to at least partially oxidize the first epitaxial silicon layer in the region, and locally etching the SOI substrate in the region to create a trench through the buried oxide layer and to the bulk silicon substrate. The method further includes forming a second epitaxial layer on the bulk silicon substrate in the trench, and forming one or more semiconductor devices in the first and second epitaxial layers.

Abstract: Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.

Abstract: The present disclosure provides a method and a device for determining a motion parameter of an autonomous mobile device. The method includes: an anti-fall sensor detects a current chassis-floor distance between a chassis of the autonomous mobile device and a current floor, and transmits the current chassis-floor distance to a processor; the processor determines a correction coefficient corresponding to the current chassis-floor distance; the processor obtains an output of an optic flow sensor; the processor determines the motion parameter corresponding to the current chassis-floor distance based on a correction coefficient, a calibration coefficient, and the output of the optic flow sensor, which increases the accuracy of the motion parameter obtained through computation.

Abstract: Provided are a phase-shifting unit, an antenna unit, a phased array unit, and a phased array. The phase-shifting unit includes a common port, a switch, and two connection ports. A transmission line between the two connection ports is provided with at least two branch ports. Positions of the at least two branch ports on the transmission line are different. The transmission line between every two adjacent branch ports includes a delay line. The switch is configured to switch to a target branch port and establish the connection between the target branch port and the common port so that the common port is connected to the two connection ports to form two paths. Each path is configured to establish the communication connection between the connection port corresponding to each path and the common port to transmit a signal.